Showing 1 – 1 of 1
Relevance | Newest | Oldest |
  • JAMA Original Investigation
    April 8, 2024

    Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

    Steven E.听Nissen,听MD; Kathy听Wolski,听MPH; Gerald F.听Watts,听MD, DSc; Michael J.听Koren,听MD; Henry听Fok,听MBBS, PhD; Stephen J.听Nicholls,听MBBS, PhD; David A.听Rider,听PhD; Leslie听Cho,听MD; Steven听Romano,听MD; Carrie听Melgaard,听MS; Curtis听Rambaran,听MBBS, MD
    Abstract Full Text
    JAMA. 2024; 331(18):1534-1543. 10.1001/jama.2024.4504

    This phase 1 randomized study assesses the safety and tolerability of zerlasiran, a short interfering RNA targeting hepatic synthesis of apolipoprotein(a), and its effects on serum concentrations of lipoprotein(a), in healthy participants and patients with stable atherosclerotic cardiovascular disease.